



Eagle Health Holdings Limited

ASX Announcement

3 June 2019

Change of Director's Interest

Eagle Health Holdings Limited (the **Company**) advises that the Company's Managing Director Mr Zhang Mingwang has disposed a total of 33,290,000 fully paid ordinary shares (**Shares**) in the Company via off-market transfers (**Disposal of Shares**).

Mr Zhang comments on the Disposal of Shares: "The Disposal of Shares will result in a reduction in the shareholding that I hold as a founding shareholder through Creator Global Holdings Limited. However, post the Disposal of Shares, Creator Global Holdings Limited still holds 91,201,757 Shares and the Disposal of Shares is expected to increase trading liquidity and free float of the Company's Shares."

Appendix 3Y is attached to this announcement.

-END

CONTACT

Steven Shao

Investor Relations

T: +61 3 8593 7378

E: steven@aeuh.com.au

Kobe Li

Company Secretary

T: +61 3 8593 7378

E: kobeli@aeuh.com.au

About Eagle Health Holdings Limited

Eagle Health is an ASX listed vertically integrated health and nutritional products business which develops, manufactures and distributes products into 26 provinces in China. Eagle Health produces a range of traditional Chinese Medicine and Western nutritional products including amino acids, protein supplements, lozenges and dendrobium oil. Eagle Health has a GMP certified manufacturing facility and a Head Office in Xiamen, China, acting as a central hub for distribution into Chinese pharmacies, health food stores, trading companies and supermarkets. Eagle Health has a corporate and sales office in Melbourne, Australia. Eagle Health has a stated strategy of acquiring or partnering with quality Australian products for distribution into China.

For more information visit: www.aeuh.com.au or www.eaglehealthltd.com/EN/index.aspx

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: Eagle Health Holding Limited
ABN: 62 616 382 515

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Zhang Mingwang
Date of last notice	27 May 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (j) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Creator Global Holdings Limited Zhang Mingwang is the sole director and shareholder of this company.
Date of change	29 and 31 May 2019
No. of securities held prior to change	124,491,757
Class	Fully Paid Ordinary Shares (Shares)
Number acquired	Nil
Number disposed	33,290,000 (17,140,000 on 29 May 2019 and 16,150,000 on 31 May 2019)
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$0.25 per Share for 17,140,000 Shares \$0.20 per Share for 16,150,000 Shares
No. of securities held after change	91,201,757

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Off-market trade</p>
--	-------------------------

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
<p>No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed</p>	N/A
Interest acquired	N/A
Interest disposed	N/A
<p>Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation</p>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

<p>Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?</p>	<p>N/A (not during a closed period, however, written clearance was obtained in accordance with the Company's Share Trading Policy)</p>
<p>If so, was prior written clearance provided to allow the trade to proceed during this period?</p>	<p>N/A</p>
<p>If prior written clearance was provided, on what date was this provided?</p>	<p>N/A</p>

⁺ See chapter 19 for defined terms.

For personal use only